Graves' Disease
Stories
-
Biohaven registers Phase 2b/3 study of BHV-1300 in Graves' Disease
The study, led by Biohaven Therapeutics Ltd., plans to enroll an estimate of 356 participants to evaluate the safety and tolerability of BHV-1300 in adults with Graves' Disease. It plans to start in October 2026 and reach primary completion in December 2028.